Carlson Douglas R 4

What Happened

• Douglas R. Carlson, Chief Financial Officer of Avalyn Pharma (AVLN), was granted a derivative award (an option) covering 211,975 shares on 2026-04-30. The Form 4 reports an acquisition price of $0.00 for the award (transaction code A).

Key Details

• Transaction date: 2026-04-30; reported acquisition price: $0.00; amount: 211,975 shares (derivative option award).
• Vesting: per the filing footnote, 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six equal monthly installments thereafter, subject to continued service.
• Shares owned after the transaction: not specified in the information provided.
• Filing: Form 4 filed 2026-05-01 — appears timely (filed within the normal reporting window). Transaction code A denotes an award/grant.

Context

• This was a compensation grant of options, not a market purchase or sale — there was no immediate sale or exercise reported. Such awards are common for executive compensation and reflect future potential ownership if/when options vest and are exercised, rather than an immediate insider investment signal.